Institutional Fund
Cormorant Asset Management, LP
Boston, MACIK 15839775 filings on record
Portfolio Value
$1.98B
Q1 2026
Holdings
46
Reported positions
New Buys
17
Opened this quarter
QoQ Change
+12.4%
from $1.76B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Praxis Precision Medicines I14.4%
- Bridgebio Oncology Therapeut8.1%
- Eyepoint Pharmaceuticals Inc5.4%
- Edgewise Therapeutics Inc5.2%
- Erasca Inc4.7%
- Rapport Therapeutics Inc4.7%
- Other57.6%
Portfolio Holdings
46 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I | 885.5K | $285.30M | 14.4% | −64.5K | Reduced |
| 2 | Bridgebio Oncology Therapeut | 17.88M | $160.01M | 8.1% | 0 | Held |
| 3 | Eyepoint Pharmaceuticals Inc | 8.27M | $106.54M | 5.4% | 0 | Held |
| 4 | Edgewise Therapeutics Inc | 3.26M | $102.69M | 5.2% | −25.0K | Reduced |
| 5 | Erasca Inc | 5.80M | $93.84M | 4.7% | +5.80M | New |
| 6 | Rapport Therapeutics Inc | 2.96M | $92.54M | 4.7% | −70.0K | Reduced |
| 7 | Alumis Inc | 3.95M | $87.00M | 4.4% | +313.6K | Added |
| 8 | Abivax SA | 760.0K | $84.63M | 4.3% | −590.0K | Reduced |
| 9 | Moonlake Immunotherapeutics | 4.48M | $83.52M | 4.2% | +125.0K | Added |
| 10 | Dianthus Therapeutics Inc | 950.0K | $79.72M | 4.0% | +950.0K | New |
36 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio